Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025
High Triple-Digit Million-Euro Sales Forecasted From 2024
Adalimumab, pegfilgrastim and tocilizumab are three of the five biosimilar products disclosed by Fresenius Kabi. • Source: Shutterstock 
